Squar Milner Financial Services LLC Acquires 223 Shares of Bristol-Myers Squibb Co (BMY)

Squar Milner Financial Services LLC lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 5.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,209 shares of the biopharmaceutical company’s stock after buying an additional 223 shares during the quarter. Squar Milner Financial Services LLC’s holdings in Bristol-Myers Squibb were worth $200,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Investment Counsel Inc boosted its stake in Bristol-Myers Squibb by 3.4% during the fourth quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 200 shares in the last quarter. Seizert Capital Partners LLC boosted its stake in Bristol-Myers Squibb by 3.8% during the fourth quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 224 shares in the last quarter. Modera Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 4.3% during the fourth quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 229 shares in the last quarter. Clear Harbor Asset Management LLC boosted its stake in Bristol-Myers Squibb by 2.4% during the first quarter. Clear Harbor Asset Management LLC now owns 9,637 shares of the biopharmaceutical company’s stock worth $460,000 after acquiring an additional 229 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Bristol-Myers Squibb by 0.8% during the fourth quarter. Cetera Investment Advisers now owns 29,595 shares of the biopharmaceutical company’s stock worth $1,537,000 after acquiring an additional 230 shares in the last quarter. Institutional investors own 74.09% of the company’s stock.

BMY opened at $46.85 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.79 and a current ratio of 1.93. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69. The stock has a market cap of $76.63 billion, a P/E ratio of 11.77, a PEG ratio of 2.19 and a beta of 0.77.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The company had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm earned $0.94 earnings per share. The firm’s revenue was up 14.0% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.18 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

BMY has been the topic of a number of recent research reports. Barclays raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $53.00 to $55.00 in a research note on Friday, May 3rd. Bank of America set a $53.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Friday, January 25th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Monday, April 8th. Credit Suisse Group set a $59.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 4th. Finally, ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $57.64.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2019/05/19/squar-milner-financial-services-llc-acquires-223-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What is a Stop Order?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.